Sarcogenics
PrivateLast Round
Grant
Apr 23, 2025
Total Funding Raised
$749,220
Company Overview
Sarcogenics is a biotechnology company developing a decellularized muscle matrix scaffold to regenerate muscle tissue for patients suffering from traumatic injuries.
Sector
Healthcare & Life Sciences
Verticals
Medical Devices, Biotechnology, Defense Tech
Business Model
B2B
Customer Profile
Government Contracts, Services & Consulting
AI Layer
Non-AI
Keywords
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Sarcogenics Comparables
Compare Sarcogenics with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| GenAssist, Inc. | 92% | |
| ECM Therapeutics, Inc. | 71% | |
| Cook MyoSite, Inc. | 70% | |
Sarcogenics Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Grant | Apr 23, 2025 | ||||
| Grant | Oct 27, 2022 |
Sarcogenics Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| U.S. Department of War | Grant |
Market signals
Structured signals derived from secondary market and firmographic data.
- Apr 23, 2025
Received $749K from the U.S. Department of War.
- Oct 27, 2022
Received grant funding.
Sarcogenics Filings
SEC and related filings with document metadata.
| Typed | Date | Amount Offered | Amount Sold | Filling | Pages | Download |
|---|---|---|---|---|---|---|
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Frequently Asked Questions
Common questions about Sarcogenics's valuation, stock price, and market status.